Ironwood Pharmaceuticals said it will present new research at PIFRS2026 on its investigational GLP-2 analog for adults with short bowel syndrome and intestinal failure. It will also share provider views on unmet needs; long-term data are planned for ESPEN2026.
published
Ironwood Pharmaceuticals said it will present new research at PIFRS2026 on its investigational GLP-2 analog for adults with short bowel syndrome and intestinal failure. It will also share provider views on unmet needs; long-term data are planned for ESPEN2026.
Latest documented BWB result
BWB member result
Exit /ES with a 14 Pt (56 tick) profit
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.